{
    "paper_id": "c9628d9ac274d744dd89c708503923943400880a",
    "metadata": {
        "title": "Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting 3 the SARS-CoV-2 spike protein 4 5 AUTHORS",
        "authors": [
            {
                "first": "Seth",
                "middle": [
                    "J"
                ],
                "last": "Zost",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Pavlo",
                "middle": [],
                "last": "Gilchuk",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Rita",
                "middle": [
                    "E"
                ],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Washington University",
                    "location": {
                        "addrLine": "17",
                        "postCode": "63110",
                        "settlement": "St. Louis",
                        "region": "MO",
                        "country": "USA 18"
                    }
                },
                "email": ""
            },
            {
                "first": "James",
                "middle": [
                    "Brett"
                ],
                "last": "Case",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Joseph",
                "middle": [
                    "X"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Reidy",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Andrew",
                "middle": [],
                "last": "Trivette",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Rachel",
                "middle": [
                    "S"
                ],
                "last": "Nargi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Rachel",
                "middle": [
                    "E"
                ],
                "last": "Sutton",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Naveenchandra",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Suryadevara",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Elaine",
                "middle": [
                    "C"
                ],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Elad",
                "middle": [],
                "last": "Binshtein",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Swathi",
                "middle": [],
                "last": "Shrihari",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Washington University",
                    "location": {
                        "addrLine": "63110, 27 MO",
                        "settlement": "St. Louis",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Mario",
                "middle": [],
                "last": "Ostrowski",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Toronto",
                    "location": {
                        "postCode": "21",
                        "settlement": "Toronto",
                        "region": "ON",
                        "country": "Canada"
                    }
                },
                "email": ""
            },
            {
                "first": "Helen",
                "middle": [
                    "Y"
                ],
                "last": "Chu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Division of Allergy and Infectious Diseases",
                    "institution": "University of Washington",
                    "location": {
                        "postCode": "98109, 22",
                        "settlement": "Seattle",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Jonathan",
                "middle": [
                    "E"
                ],
                "last": "Didier",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Berkeley Lights, Inc",
                    "location": {
                        "postCode": "94608",
                        "settlement": "Emeryville",
                        "region": "CA",
                        "country": "USA 23"
                    }
                },
                "email": ""
            },
            {
                "first": "Keith",
                "middle": [
                    "W"
                ],
                "last": "Macrenaris",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Berkeley Lights, Inc",
                    "location": {
                        "postCode": "94608",
                        "settlement": "Emeryville",
                        "region": "CA",
                        "country": "USA 23"
                    }
                },
                "email": ""
            },
            {
                "first": "Taylor",
                "middle": [],
                "last": "Jones",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Samuel",
                "middle": [],
                "last": "Day",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Luke",
                "middle": [],
                "last": "Myers",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "F",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Eun-Hyung",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Emory University",
                    "location": {
                        "postCode": "30322",
                        "settlement": "Atlanta",
                        "region": "GA",
                        "country": "USA 24"
                    }
                },
                "email": ""
            },
            {
                "first": "Doan",
                "middle": [
                    "C"
                ],
                "last": "Nguyen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Emory University",
                    "location": {
                        "postCode": "30322",
                        "settlement": "Atlanta",
                        "region": "GA",
                        "country": "USA 24"
                    }
                },
                "email": ""
            },
            {
                "first": "Ignacio",
                "middle": [],
                "last": "Sanz",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Emory University",
                    "location": {
                        "postCode": "30322",
                        "settlement": "Atlanta",
                        "region": "GA",
                        "country": "USA 24"
                    }
                },
                "email": ""
            },
            {
                "first": "David",
                "middle": [
                    "R"
                ],
                "last": "Martinez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of North",
                    "location": {
                        "addrLine": "Carolina at Chapel Hill, Chapel Hill, 25 NC",
                        "postCode": "27599",
                        "country": "USA 26"
                    }
                },
                "email": ""
            },
            {
                "first": "Ralph",
                "middle": [
                    "S"
                ],
                "last": "Baric",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of North",
                    "location": {
                        "addrLine": "Carolina at Chapel Hill, Chapel Hill, 25 NC",
                        "postCode": "27599",
                        "country": "USA 26"
                    }
                },
                "email": ""
            },
            {
                "first": "Larissa",
                "middle": [
                    "B"
                ],
                "last": "Thackray",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Washington University",
                    "location": {
                        "addrLine": "63110, 27 MO",
                        "settlement": "St. Louis",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [
                    "S"
                ],
                "last": "Diamond",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Washington University",
                    "location": {
                        "addrLine": "17",
                        "postCode": "63110",
                        "settlement": "St. Louis",
                        "region": "MO",
                        "country": "USA 18"
                    }
                },
                "email": ""
            },
            {
                "first": "Robert",
                "middle": [
                    "H"
                ],
                "last": "Carnahan",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "James",
                "middle": [
                    "E"
                ],
                "last": "Crowe",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Vanderbilt University Medical Center",
                    "location": {
                        "addrLine": "15",
                        "postCode": "37232",
                        "settlement": "Nashville",
                        "region": "TN",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Andrew",
                "middle": [
                    "M"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jane",
                "middle": [
                    "M"
                ],
                "last": "Bursky",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "IDBiologics, Inc. Vanderbilt University has applied for patents concerning SARS-CoV-2 231 antibodies that are related to this work. Emory University has applied for a patent concerning ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sanofi and is on the Scientific Advisory Boards of CompuVax and Meissa Vaccines, is a 229 recipient of previous unrelated research grants from Moderna and Sanofi and is Founder of 230"
        },
        {
            "text": "healthy subject (subject 6). Plots show CD19 + IgD -IgMpopulation using gating strategy 264 as in b. Cells labeled with biotinylated S2P ecto or RBD-mFc antigens were detected using 265 phycoerythrin (PE)-conjugated streptavidin. 266 d. Plasma or serum neutralizing activity against the WA1/2020 strain SARS-CoV-2 for 267 subjects 1 to 4 or a healthy donor (subject 6). % neutralization is reported. white indicates neutralizing activity was not detected. Based on both binding and 296 neutralization, we grouped the mAbs into classes. Class I mAbs bind to both S2P ecto and 297 S RBD proteins and are SARS-CoV-2 specific; Class II mAbs also bind to both S2P ecto and 298 S RBD proteins and cross-react with SARS-CoV; Class III mAbs bind to both S2P ecto and 299 S NTD proteins and are mostly SARS-CoV-2 specific; Class IV mAbs bind only to S2P ecto 300 protein and are SARS-CoV-2 specific; Class V mAbs bind only to S2P ecto protein and 301 cross-react with SARS-CoV. The frequency counts are derived from the total number of unique sequences with the 306 corresponding V and J genes. The V/J frequency counts then were transformed into a z-307 score by first subtracting the average frequency, then normalizing by the standard 308 deviation of each subject. Red denotes more common gene usage, while blue denotes 309 less common gene usage. e. CDR3 amino acid length distribution. The CDR3 of each sequence was determined 311",
            "cite_spans": [],
            "ref_spans": [],
            "section": "c. Analytical flow cytometric analysis of B cells for subjects 1 to 4, compared to a 263"
        },
        {
            "text": "using PyIR software. The amino acid length of each CDR3 was counted. The 312 distribution of CDR3 amino acid lengths for heavy or light chains then was plotted as a 313 histogram and fitted using kernel density estimation for the curves. h. Quantitative test for neutralizing activity against SARS-CoV using a nano-327 luciferase virus. A representative purified mAb that exhibited cross-reactive binding to 328 SARS-CoV S2P ecto protein in (b) above and that also exhibited full neutralizing activity 329",
            "cite_spans": [],
            "ref_spans": [],
            "section": "c. Analytical flow cytometric analysis of B cells for subjects 1 to 4, compared to a 263"
        },
        {
            "text": "in the screening neutralization test in (c) above was tested in a serial dilution series in a 330 neutralization test with a recombinant, reverse-genetics-derived SARS-CoV encoding a 331 nano-luciferase reporter gene, and reduction of luciferase activity was used to calculate 332 % neutralization. Values shown are the mean of two technical replicates, and error bars 333 denote the standard deviation for each point. coronavirus by a human mAb to S1 protein that blocks receptor association. Proc 395 Natl Acad Sci U S A 101, 2536-2541 (2004) . 10 -5 10 -4 10 -3 10 -2 10 -1 10 -5 10 -4 10 -3 10 -2 10 -1 10 -5 10 -4 10 -3 10 -2 10 -1 10 -5 10 -4 10 -3 10 -2 10 -1 Research subjects. We studied four subjects in North America with recent laboratory-3 confirmed symptomatic SARS-CoV-2 infection that were acquired in China ( Table S1) on January 19, 2020 1 , a blood sample was obtained for study on February 19, 2020. Subject 2 10 (52-year-old female) was infected following close exposure in Beijing, China to an infected 11 person from Wuhan, China during the period between January 23 to January 29, 2020. She 12 presented with mild respiratory disease symptoms from February 1 to 4, 2020 that occurred presented to a hospital in Toronto, January 23, 2020 complaining of fever, cough and 21 shortness of breath; a nasopharyngeal swab was positive by PCR testing for SARS-CoV-2. His 22 chest x-ray at that time was abnormal, and he was admitted for non-ICU impatient care. He 23 improved gradually with supportive care, was discharged January 30, 2020 and rapidly 24 became asymptomatic except for a residual dry cough that persisted for a month. He had a 25 negative nasopharyngeal swab PCR test on February 19, 2020. Subject 4 is the wife of subject 3 26 who traveled with her husband from Wuhan. She was never symptomatic with respiratory 27 symptoms or fever but was tested because of her exposure. Her nasopharyngeal swab was 28 positive for SARS-CoV-2 by PCR, on January 24, 2020; repeat testing in followup on February 29 21, 2020 was negative. PBMCs were obtained by leukopheresis from subjects 3 and 4 on 30",
            "cite_spans": [
                {
                    "start": 528,
                    "end": 544,
                    "text": "2536-2541 (2004)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 826,
                    "end": 835,
                    "text": "Table S1)",
                    "ref_id": null
                }
            ],
            "section": "c. Analytical flow cytometric analysis of B cells for subjects 1 to 4, compared to a 263"
        },
        {
            "text": "March 10, 2020, which was 50 days since the symptom onset of subject 3. Samples were 31 Disease Control and Prevention (a gift from Natalie Thornburg). Virus was passaged in Vero 50",
            "cite_spans": [],
            "ref_spans": [],
            "section": "c. Analytical flow cytometric analysis of B cells for subjects 1 to 4, compared to a 263"
        },
        {
            "text": "CoV-2 was approved by the Washington University School of Medicine or UNC-Chapel Hill 52",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CCL81 cells and titrated by plaque assay on Vero E6 cells. All work with infectious SARS-51"
        },
        {
            "text": "Institutional Biosafety Committees and conducted in approved BSL3 facilities using 53 appropriate powered air purifying respirators and personal protective equipment. 54 55 Recombinant antigens and proteins. A gene encoding the ectodomain of a prefusion 56 conformation-stabilized SARS-CoV-2 spike (S2P ecto ) protein was synthesized and cloned into a 57 DNA plasmid expression vector for mammalian cells. A similarly designed S protein antigen 58 with two prolines and removal of the furin cleavage site for stabilization of the prefusion form 59 of S was reported previously 3 . Briefly, this gene includes the ectodomain of SARS-CoV-2 (to 60 residue 1,208), a T4 fibritin trimerization domain, an AviTag site-specific biotinylation 61 sequence, and a C-terminal 8x-His tag. To stabilize the construct in the prefusion 62 conformation, we included substitutions K968P and V969P and mutated the furin cleavage 63 site at residues 682-685 from RRAR to ASVG. This recombinant spike 2P-stabilized protein 64 (designated here as S2P ecto ) was isolated by metal affinity chromatography on HisTrap Excel 65 columns (GE Healthcare), and protein preparations were purified further by size-exclusion 66 chromatography on a Superose 6 Increase 10/300 column (GE Healthcare). The presence of 67 trimeric, prefusion conformation S protein was verified by negative-stain electron microscopy 68 ( Figure S1 ). To express the S RBD subdomain of SARS-CoV-2 S protein, residues 319-541 were 69 cloned into a mammalian expression vector downstream of an IL-2 signal peptide and 70 upstream of a thrombin cleavage site, an AviTag, and a 6x-His tag. RBD protein fused to 71 mouse IgG1 Fc domain (designated RBD-mFc), was purchased from Sino Biological (40592-72 V05H). For B cell labeling and sorting, RBD-mFc and S2P ecto proteins were biotinylated using 73 the EZ-Link\u2122 Sulfo-NHS-LC-Biotinylation Kit and vendor's protocol (ThermoFisher 74 Scientific, 21435). 75",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1385,
                    "end": 1394,
                    "text": "Figure S1",
                    "ref_id": null
                }
            ],
            "section": "CCL81 cells and titrated by plaque assay on Vero E6 cells. All work with infectious SARS-51"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "First case of 2019 novel coronavirus in the United States",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Holshue",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "N",
            "volume": "345",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Enhancing dengue virus maturation using a stable furin 348 over-expressing cell line",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mukherjee",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Virology",
            "volume": "497",
            "issn": "",
            "pages": "33--40",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Cryo-EM structure of the 2019-nCoV spike in the prefusion 351 conformation",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wrapp",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "1260--1263",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Negative staining and image classification -354",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ohi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Walz",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Powerful tools in modern electron microscopy",
            "authors": [],
            "year": 2004,
            "venue": "Biol Proced Online",
            "volume": "6",
            "issn": "",
            "pages": "23--34",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Automated electron microscope tomography using robust 357 prediction of specimen movements",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "N"
                    ],
                    "last": "Mastronarde",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Struct Biol",
            "volume": "152",
            "issn": "",
            "pages": "36--51",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "cryoSPARC: algorithms 360 for rapid unsupervised cryo-EM structure determination",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Punjani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Rubinstein",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Fleet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Brubaker",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Nat Methods",
            "volume": "14",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Topaz-Denoise: general deep denoising 364 models for cryoEM",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Bepler",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Noble",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Berger",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/838920"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "UCSF Chimera--a visualization system for exploratory 367 research and analysis",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "F"
                    ],
                    "last": "Pettersen",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Comput Chem",
            "volume": "25",
            "issn": "",
            "pages": "1605--1612",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Analysis of a therapeutic antibody cocktail reveals determinants 370 for cooperative and broad ebolavirus neutralization",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gilchuk",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Immunity",
            "volume": "52",
            "issn": "",
            "pages": "388--403",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Factors of the bone marrow microniche that support human 374 plasma cell survival and immunoglobulin secretion",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nat Commun",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "An efficient 377 method to generate monoclonal antibodies from human B cells",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Guthmiller",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "L"
                    ],
                    "last": "Dugan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Neu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Wilson",
                    "suffix": ""
                }
            ],
            "year": 1904,
            "venue": "Methods Mol Biol",
            "volume": "378",
            "issn": "",
            "pages": "109--145",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "PyIR: A scalable wrapper for processing billions of 382 immunoglobulin and T cell receptor sequences using IgBLAST",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Branchizio",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Crowe",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "384",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Cleavage efficient 2A peptides for high level monoclonal antibody 385 expression in CHO cells",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chng",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "MAbs",
            "volume": "7",
            "issn": "",
            "pages": "403--412",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Integrated technology platform for accelerated discovery of 393 antiviral antibody therapeutics",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Carnahan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature Medicine",
            "volume": "395",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "A highly conserved cryptic epitope in the receptor binding 396 domains of SARS-CoV-2 and SARS-CoV",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "368",
            "issn": "",
            "pages": "630--633",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Reverse genetics with a full-length infectious cDNA of the 399",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Scobey",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Middle East respiratory syndrome coronavirus",
            "authors": [],
            "year": 2013,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "110",
            "issn": "",
            "pages": "16157--16162",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Reverse genetics with a full-length infectious cDNA of severe 403 acute respiratory syndrome coronavirus",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yount",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "100",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "232 the plasmablast survival medium. J.E.D. and K.W.M. are employees of Berkeley Lights, Inc. 233 All other authors declared no competing interests. 234 235 Data availability. All relevant data are included with the manuscript. Workflows and timelines. 240 a. Overview of rapid monoclonal antibody discovery workflows. The overall scheme 241 is shown, representing the seven specific workflows conducted in parallel (specified in 242 Table S2). Blood was collected and white blood cells separated, B cells were enriched 243 from PBMCs by negative selection using paramagnetic beads, antigen-specific cells 244 were obtained by flow cytometric sorting, then processed for direct B cell selection and 245 sequencing or in vitro expansion/activation. Cultured B cells were loaded on a Beacon 246 instrument (Berkeley Lights) for functional screening (Figure S2, Movie S1) or in a 247 Chromium device (10X Genomics) followed by RT-PCR, sequence analysis, cDNA gene 248 synthesis and cloning into an expression vector, and microscale IgG expression in CHO 249 cells by transient transfection. Recombinant IgG was tested by ELISA for binding to 250 determine antigen reactivity and by a cell impedance-based neutralization test 251 (xCelligence; ACEA) (Figure S3) with live virus in a BSL3 laboratory for functional 252 characterization. 253 Characterization of SARS-CoV-2 immune donor samples. 255 a. Serum or plasma antibody reactivity for the four SARS-CoV-2 immune subjects or 256 one non-immune control, in ELISA using SARS-CoV-2 S2P ecto , S RBD , S NTD , SARS-CoV 257 S2P ecto or PBS. 258 b. Gating for memory B cells in total B cells enriched by negative selection using 259 magnetic beads for subject 4; Cells were stained with anti-CD19 antibody conjugated to 260 allophycocyanin (APC) and anti-IgM and anti-IgD antibodies conjugated to fluorescein 261 isothiocyanate (FITC).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "268 e. FACS isolation of S2P ecto or RBD-mFc-reactive B cells from pooled B cells of subject 3 269 and 4. Plots show CD19 + IgD -IgMpopulation using gating strategy as in b, and antigen-270 reactive B cells were identified as in c. 271 f. Lymphoblastoid cell line (LCL) supernatant neutralization. Neutralization of the 272 WA1/2020 strain SARS-CoV-2 by supernatant collected from cell cultures of S2P ecto -or 273 RBD-mFc-sorted memory B cells that had been stimulated in bulk in vitro on feeder 274 layers expressing CD40L and secreting IL-21 and BAFF. The supernatants were tested 275 in a ten-point dilution series in the FRNT, and % neutralization is reported. Values 276 shown are the mean \u00b1 SD of technical duplicates. 277 Reactivity and functional activity of 386 human mAbs. 279 a. Structures of SARS-CoV-2 spike antigen. Top panel: S protein monomer of SARS-280 CoV-2 highlighting RBD (blue) and NTD (red) subdomains that were expressed as 281 recombinant proteins. The ACE2 binding site on RBD is shown in orange. Known 282 glycans are shown as light grey spheres. (PDB 6VYB) Middle panel: the structure of 283 trimeric SARS-CoV-2 spike with one RBD in the \"head up\" conformation. Bottom panel: 284 structure (PDB 6M0J) of SARS-CoV-2 RBD (blue) and ACE2 (pink) highlighting 285 differences between RBDs of SARS-CoV-2 and SARS-CoV (cyan). b. MAbs binding to each of four S proteins or subdomains. The figure shows a 287 heatmap for binding of 386 mAbs expressed recombinantly, representing optical 288 density (O.D.) values collected at 450 nm for each antigen (range 0.035 to 4.5). White 289 indicates lack of detectable binding, while blue indicates binding, with darker blue 290 indicating higher O.D. values. 291 c. Screening test for neutralizing activity. Each mAb was tested in a cell-impedance 292 based neutralization test (Figure S3) using Vero-furin cells and live WA1/2020 strain 293 SARS-CoV-2 in a BSL3 laboratory. Green indicates full protection of cells (full 294 neutralization), purple indicates partial protection of cells, (partial neutralization), and 295",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "302 d. Heatmap showing usage of antibody variable gene segments for variable (V) and 303 joining (J) genes. Of the 386 antibodies tested in (b) and (c) above, 324 were found to 304have unique sequences, and those unique sequences were analyzed for genetic features.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "314 f. Divergence from inferred germline gene sequences. The number of mutations from 315 each inferred unmutated ancestor sequence in the region spanning from antibody 316 framework region 1 to 4 was counted up for each chain. These numbers then were 317 transformed into percent values and plotted as violin plots.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "318g. Quantitative test for neutralizing activity against SARS-CoV-2 using FRNT. 319Representative mAbs that exhibited full neutralizing activity in the screening 320 neutralization test in (c) above using micro-scale expression were prepared in midi-321scale as purified IgG and tested in a serial dilution series in the FRNT with live 322 WA1/2020 strain SARS-CoV-2 to demonstrate neutralizing potency of class-323 representative mAbs. % neutralization of virus infection (relative to control wells with 324 no mAb) at each dilution is shown. Values shown are the mean of two technical 325 replicates, and error bars denote the standard deviation for each point.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Expression and validation of prefusion-stabilized SARS-CoV-2 S2P ecto 339 protein. 340 a. Reducing SDS-PAGE gel indicating S2P ecto protein migrating at approximately 341 180KDa. 342 b. Representative micrograph of negative-stain electron microscopy with S2P ecto 343 protein preparation. Scale bar denotes 100 nm. 344 c. 2D class-averages of S2P ecto protein in the prefusion conformation. The size for each 345 box is 128 pixels. 346 Functional assays from single antigen-reactive B cells. 348 a. Schematic of detection of antigen-specific antibody. Biotinylated antigen (dark 349 grey) was coupled to a streptavidin-conjugated polystyrene bead (light grey). 350 Antibodies (blue) are secreted by single B cells loaded into individual NanoPens on the 351 Berkeley Lights Beacon optofluidic device. Antibody binding to antigen was detected 352 with a fluorescent anti-human IgG secondary Ab (black). 353 b. Left: Schematic of fluorescing beads in the channel above a pen containing an 354 individual B cell indicates antigen-specific reactivity. 355 Top right: False-color still image of positive wells with B cells secreting S2P ecto -356 reactive antibodies. Reactive antibody diffusing out of a pen is visualized as a plume of 357 fluorescence. 358 Bottom right: False-color still image of positive wells with B cells secreting RBD-359 mFc-reactive antibodies. c. Representative images of RBD-mFc reactive clones. 360 361 Figure S3. Real-time cell analysis assay to screen for neutralization activity. a. Representative sensograms for neutralizing mAbs. Curves for fully neutralizing mAb 363 (green) and partially neutralizing mAb (red) by monitoring of CPE in Vero-furin cells that 364 were inoculated with SARS-CoV-2 and pre-incubated with the respective mAb. Uninfected 365 cells (blue) and infected cells without antibody addition (grey) served as controls for intact 366 monolayer and full CPE, respectively. Data represented single well measurement for each 367 mAb and mean SD values of technical duplicates or quadruplicates for the controls. 368 b. Example sensograms from individual wells of 384-well E-plate analysis showing rapid 369 identification of SARS-CoV-2 neutralizing mAbs. Neutralization was assessed using 370 micro-scale purified mAbs and each mAb was tested in four 5-fold dilutions as indicated. 371 Plates were measured every 8-12 hours for a total of 72 hrs as in (a). 372 373 374 Movie S1. Time-lapse imaging of antigen-sorted single B cells secreting S2P ecto -375 reactive antibodies. A field of view of the optofluidic chip is shown with single B cells 376 at the bottom of NanoPens, as in Figure S1. Antigen-reactive antibody bound to S2P ecto 377 antigen conjugated to streptavidin polystyrene beads loaded into the channel is 378 detected by an anti-IgG secondary antibody. Positive wells are identified by the specific 379 bloom of fluorescence signal, indicating antigen-specific antibody diffusing out of a 380 single pen. The edges of pens are highlighted in green and pen numbers are shown in 381 yellow. For that field of view, there were 96 pens containing B cells, with 53 cells 382 secreting trimer-reactive antibody and 30 cells secreting antibody reactive to RBD. The 383 movie is composed of still images obtained every five minutes over the course of a 30-384 minute assay. 385 1. Zhou, P., et al. A pneumonia outbreak associated with a new coronavirus of 388 probable bat origin. Nature 579, N., et al. A novel coronavirus from patients with pneumonia in China, 2019. 391 N Engl J Med 382, J., et al. Potent neutralization of severe acute respiratory syndrome (SARS) 394",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": ", J., et al. Human monoclonal antibody as prophylaxis for SARS 398 coronavirus infection in ferrets. Lancet 363, 2139-2141 (2004). 399 400 5. ter Meulen, J., et al. Human monoclonal antibody combination against SARS 401 coronavirus: synergy and coverage of escape mutants. PLoS Med 3, e237 (2006). 402 403 6. Zhu, Z., et al. Potent cross-reactive neutralization of SARS coronavirus isolates by 404 human monoclonal antibodies. Proc Natl Acad Sci U S A 104, 12123-12128 (2007). 405 406 7. Rockx, B., et al. Structural basis for potent cross-neutralizing human monoclonal 407 antibody protection against lethal human and zoonotic severe acute respiratory 408 syndrome coronavirus challenge. J Virol 82, 3220-3235 (2008). 409 8. Chen, Z., et al. Human neutralizing monoclonal antibody inhibition of Middle East 411 respiratory syndrome coronavirus replication in the common marmoset. , J.H., et al. Characterization of a human monoclonal antibody generated from 415 a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory 416 syndrome coronavirus. PLoS One 15, e0232757 (2020). 417 418 10. Niu, P., et al. Ultrapotent human neutralizing antibody repertoires against Middle 419 East respiratory syndrome coronavirus from a recovered patient. J Infect Dis 218, , L., et al. Importance of neutralizing monoclonal antibodies targeting 423 multiple antigenic sites on the Middle East respiratory syndrome coronavirus 424 spike glycoprotein to avoid neutralization escape. J Virol 92(2018). 425 426 12. Wang, N., et al. Structural Definition of a Neutralization-Sensitive Epitope on the 427 MERS-CoV S1-NTD. Cell Rep 28, 3395-3405 e3396 (2019). 428 429 13. Zhang, S., et al. Structural definition of a unique neutralization epitope on the 430 receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep 24, D., et al. Prophylactic and postexposure efficacy of a potent human 434 monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A , L., et al. Potent neutralization of MERS-CoV by human neutralizing 438 monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 6, , X.C., et al. Identification of human neutralizing antibodies against MERS-442 CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 111, , T., et al. Exceptionally potent neutralization of Middle East respiratory 446 syndrome coronavirus by human monoclonal antibodies. J Virol 88, , S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and 450 other human coronaviruses. Trends Immunol 41, 355-359 (2020). 451 452 19. Gilchuk P, B.R., Erasmus JH, Durnel LA, Nargi R, Soto C, Abbink P, Suscovich TJ, 453 Tan Q, Khandhar A, Archer J, Bryan A, Davidson E, Doranz BJ, Fouch ME, Jones 454 T, Larson E, Ertel S, Granger B, Fuerte-Stone J, Roy V, Broge T, Linnekin TC, Linde 455 CH, Gorman MJ, Nkolola J, Galit Alter G, Steven G Reed SG, Daniel H Barouch 456 DH, Michael S Diamond MS, Crowe JE Jr, Neal Hoeven N, Thackray L, Carnahan 457 R. Integrated technology platform for accelerated discovery of antiviral antibody 458 therapeutics. . Nature Medicine (2020). 459 460 20. Wrapp, D., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 461 conformation. Science 367, 1260-1263 (2020). 462 463 21. Holshue, M.L., et al. First case of 2019 novel coronavirus in the United States. N 464 Engl J Med 382, 929-936 (2020). 465 466 22. Gilchuk, P., et al. Analysis of a Therapeutic antibody cocktail reveals determinants 467 for cooperative and broad ebolavirus neutralization. Immunity 52, , C., et al. High frequency of shared clonotypes in human B cell receptor 471 repertoires. Nature 566, 398-402 (2019). 472 473 24. Wrammert, J., et al. Broadly cross-reactive antibodies dominate the human B cell 474 response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208, L.E., et al. Early human B cell Rrsponse to Ebola virus in four U.S. 478 survivors of infection. J Virol 93(2019). 479 480 26. Davis, C.W., et al. Longitudinal analysis of the human B cell response to Ebola 481 virus infection. Cell 177, 1566-1582 e1517 (2019).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "Figure S1",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": ". The 4 studies were approved by the Institutional Review Board of Vanderbilt University Medical 5 Center, and subsite studies were approved by the Institutional Review Board of the 6 University of Washington or the Research Ethics Board of the University of Toronto. Samples 7 were obtained after written informed consent. Subject 1 (35-year-old male) was the earliest 8 reported case of SARS-CoV-2 infection in the U.S. who presented with disease in Seattle, WA 9",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "13 after travel to Madison, Wisconsin, USA. She obtained a diagnosis of infection by testing at 14 the U.S. Centers for Disease Control on February 5, 2020. Blood samples were obtained for 15 study on March 7 and March 8, 2020. Subject 3 (a 56-year-old male) and subject 4 (a 56-year-16 old female) are a married couple and residents of Wuhan, China who traveled to Toronto, 17 Canada on January 22, 2020. Subject 3 first developed a cough without fever on January 20, 18 2020 in the city of Wuhan, where he had a normal chest x-ray on that day. He flew to Canada 19 with persisting cough and arrived in Canada January 22, 2020 where he became febrile. He 20",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "culture. Vero E6 (CRL-1586, American Type Culture Collection (American Type 35 Culture Collection, ATCC), Vero CCL81 (ATCC), HEK293 (ATCC), and HEK293T 36 (ATCC) were maintained at 37\u00b0C in 5% CO 2 in Dulbecco's minimal essential medium 37 (DMEM) containing 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), 10 mM 38 HEPES pH 7.3, 1 mM sodium pyruvate, 1\u00d7 non-essential amino acids, and 100 U/mL of 39 penicillin-streptomycin. Vero-furin cells were obtained from T. Pierson (NIH) and have 40 been described previously 2 . Expi293F cells (ThermoFisher Scientific, A1452) were 41 maintained at 37\u00b0C in 8% CO 2 in Expi293F Expression Medium (ThermoFisher 42 Scientific, A1435102). ExpiCHO cells (ThermoFisher Scientific, A29127) were 43 maintained at 37\u00b0C in 8% CO 2 in ExpiCHO Expression Medium (ThermoFisher 44 Scientific, A2910002). Mycoplasma testing of Expi293F and ExpiCHO cultures was 45 performed on a monthly basis using a PCR-based mycoplasma detection kit (ATCC, 30-46 1012K). 47 48 Viruses. SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the Centers for 49",
            "latex": null,
            "type": "figure"
        },
        "TABREF1": {
            "text": "Table S2. Workflows used to isolate SARS-CoV-2 specific human mAbs from",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "protein. For screening and imaging of negatively-stained (NS) SARS-CoV-2 S2P ecto 78 protein, approximately 3 \u00b5L of the sample at concentrations of about 10 to 15 \u00b5g/mL 79 was applied to a glow discharged grid with continuous carbon film on 400 square mesh 80 copper EM grids (Electron Microscopy Sciences, Hatfield, PA). The grids were stained 81 with 0.75% uranyl formate (UF) 4 . Images were recorded on a Gatan US4000 4k \u00d7 4k 82 CCD camera using an FEI TF20 (TFS) transmission electron microscope operated at 200 83 keV and control with SerialEM 5 . All images were taken at 50,000\u00b4 magnification with a 84 pixel size of 2.18 \u00c5/pix in low-dose mode at a defocus of 1.5 to 1.8 \u03bcm. Total dose for 85 the micrographs was ~25 e \u2212 /\u00c5 2 . Image processing was performed using the 86 cryoSPARC software package 6 . Images were imported, and particles were CTF 87 estimated. The images then were denoised and picked with Topaz 7 . The particles were 88 extracted with a box size of 256 pixels and binned to 128 pixels. 2D class averages were 89 performed and good classes selected for ab-initio model and refinement without 90 symmetry (see also ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Electron microscopy (EM) stain grid preparation and imaging of SARS-CoV-2 S2P ecto 77"
        },
        {
            "text": "SARS-CoV-2 in PBMCs from a cohort of four subjects with documented previous infection 96 with the virus were analyzed for antigen specificity, and PBMCs were used for SARS-CoV-2-97 specific B cell enrichment. The frequency of SARS-CoV-2 S protein-specific B cells was 98 identified by antigen-specific staining with either biotinylated S2P ecto or RBD-mFc protein. Briefly, B cells were purified magnetically (STEMCELL Technologies) and stained with anti-100 CD19-APC (clone HIB19, 982406), -IgD-FITC (clone LA6-2, 348206), and -IgM-FITC (clone 101 MNM-88, 314506) phenotyping antibodies (BioLegend) and biotinylated antigen. A 4\u2032,6-102 diamidino-2-phenylindole (DAPI) stain was used as a viability dye to discriminate dead cells. 103Antigen-labeled class-switched memory B cell-antigen complexes (CD19 + IgM -IgD -Ag + DAPI -) 104were detected with a R-phycoerythrin (PE)-labeled streptavidin conjugate (ThermoFisher 105 Scientific, S866). After identification of the two subjects with the highest B cell response 106 against SARS-CoV-2 (subjects 3 and 4), target-specific memory B cells were isolated by flow 107 cytometric sorting using an SH800 cell sorter (Sony) from pooled PBMCs of these two 108 subjects, after labeling of B cells with either biotinylated S2P ecto or RBD-mFc proteins. 109 110 Overall, from > 4 x 10 8 PBMCs, 2,126 RBD-mFc-reactive and 5,544 S2P ecto protein-reactive B 111 cells were sorted and subjected to further analysis. Several methods were implemented for the 112 preparation of sorted B cells for sequencing. Approximately 4,500 sorted cells were subjected 113 to direct sequencing immediately after flow cytometric sorting. The remaining cells were 114 expanded in culture for eight days in the presence of irradiated 3T3 feeder cells that were 115 engineered to express human CD40L, IL-21, and BAFF, as described previously 9 . The 116 expanded lymphoblastoid cell lines (LCLs) secreted high levels of S protein-specific 117 antibodies, as confirmed by ELISA to detect antigen-specific human antibodies in culture 118supernatants. Approximately 40,000 expanded LCLs were sequenced using the Chromium 119 sequencing method (10x Genomics). light is used to transfer B cells into individual nanoliter-volume chambers 127 (NanoPens\u2122). Using this light-based manipulation, thousands of LCLs were 128 transferred into pens across multiple chips in each workflow. We performed an on-chip, 129fluorescence-based assay to identify antibodies that bound SARS-CoV-2 S2P ecto or RBD-130 mFc protein. We prepared 6-to 8-micron and 10-to 14-micron RBD-mFc-conjugated 131 beads by coupling biotinylated RBD-mFc protein to streptavidin-coated polystyrene 132 particles (Spherotech Inc.). We prepared 6-to 8-micron S2P ecto protein-conjugated beads 133 by coupling full-length S2P ecto protein to streptavidin-coated polystyrene particles. 134Assays consisted of mixing beads conjugated with the RBD-mFc or S2P ecto proteins with 135 fluorescently-labeled anti-human secondary antibodies (AF568, Thermo Fisher 136 Scientific) and importing this assay mixture into OptoSelect 11k chips. Antigen-specific 137 antibodies bound the antigen-conjugated beads, which then sequestered the fluorescent 138 secondary antibody. Cells secreting antigen-specific antibodies were identified by 139 locating the NanoPens immediately adjacent to the fluorescent beads. Antigen-specific 140 cells of interest were exported from specific NanoPen chambers to individual wells of 141 96-well RT-PCR plates containing lysis buffer. 142 143 Sequencing and cloning of single antigen-specific B cells. After export from the Beacon, 144 antibody heavy and light chain sequences for B cells secreting antibodies with RBD-mFc-or 145 S2P ecto -binding antibodies were amplified and recovered using components of the 146Opto\u2122 Plasma B Discovery cDNA Synthesis Kit (Berkeley Lights). Antibody heavy and light 147 chain sequences were amplified through a 5'RACE approach using the kit's included \"BCR 148Primer 2\" forward primer and isotype-specific reverse primers. The 5'-RACE amplified cDNA 149 was sequenced using the Pacific Biosciences Sequel platform using the SMRTbell Barcoded 150Adapt Complete Prep-96 kit (Pacific Biosciences) and a 6-hour movie time. In a redundant 151 sequencing approach, heavy and light chain sequences were amplified using a cocktail of 152 custom V and J gene-specific primers (similar to previously described human Ig gene-specific 153 primers 11 ) from the original 5'-RACE-amplified cDNA while the products of the gene-specific 154 amplification were sent for Sanger sequencing (GENEWIZ). The sequences generated by these 155 two approaches were analyzed using our Python-based antibody variable gene analysis tool 156 (PyIR; https://github.com/crowelab/PyIR) 12 to identify which V and J genes most closely 157 matched the nucleotide sequence. Heavy and light chain sequences were then amplified from 158 the original cDNA using cherry-picked V and J gene-specific primers most closely 159 corresponding to the V and J gene calls made by PyIR. These primers include adapter 160 sequences which allow Gibson-based cloning into a monocistronic IgG1 expression vector 161 (pMCis_G1). Similar to a vector described below, this vector contains an enhanced 2A 162 sequence and GSG linker that allows simultaneous expression of mAb heavy and light chain 163 genes from a single construct upon transfection 13 . The pMCis_G1 vector was digested using 164 the New England BioLabs restriction enzyme FspI, and the amplified paired heavy and light 165 chain sequences were cloned through Gibson assembly using NEBuilder HiFi DNA Assembly 166Master Mix. After recovered sequences were cloned into pMCis_G1 expression constructs, 167 recombinant antibodies were expressed in Chinese hamster ovary (CHO) cells and purified 168 by affinity chromatography as detailed below. Antigen-binding activity was confirmed using 169 plate-based ELISA. Biotech) and TMB (3,3\u00a2,5,5\u00a2-tetramethylbenzidine) substrate (Thermo Fisher Scientific). 247Color development was monitored, 1N hydrochloric acid was added to stop the reaction, 248 and the absorbance was measured at 450 nm using a spectrophotometer (Biotek). For dose-249 response assays, serial dilutions of purified mAbs were applied to the wells in triplicate, 250and mAb binding was detected as detailed above. Half-maximal effective concentration 251 were 324 unique nucleotide sequences that were analyzed for V/D/J gene usage, CDR3 289 length, and somatic mutation. First, the number of sequences with corresponding V and 290 J genes were counted. The V/J frequency counts were then transformed into a z-score 291 by first subtracting away the average frequency then normalizing by the standard 292 deviation of each subject. The z-score was then plotted as a heatmap using python 293 seaborn library. The amino acid length of each CDR3 was counted. The distribution of 294 CDR3 amino acid lengths were then plotted as histograms and fitted using kernel 295 density estimation for the curves using python seaborn library. The number of 296 mutations from each inferred germ-line sequence starting from FR-1 to FR4 was 297 counted up for each chain. This number was then transformed into a percentage value. 298These values are then plotted as a categorical distribution plot as a violin plot using the 299 python seaborn.catplot library. NanoLuc virus was mixed with serially diluted antibodies. Antibody-virus complexes 321were incubated at 37\u00b0C in 5% CO 2 for 1 hr. Following incubation, growth medium was 322 removed and virus-antibody dilution complexes were added to the cells in duplicate. 323Virus-only and cell-only controls were included in each neutralization assay plate. 324Following infection, plates were incubated at 37\u00b0C in 5% CO 2 for 48 hours. After the 48-325 hour incubation, cells were lysed and luciferase activity was measured using the Nano-326Glo Luciferase Assay System (Promega), according to the manufacturer's specifications. 327 328 High-throughput mAb quantification. High-throughput quantification of micro-scale 329 produced mAbs was performed from CHO culture supernatants or micro-scale purified 330 mAbs in a 96-well plate format using the Cy-Clone Plus Kit and an iQue Plus Screener flow 331 cytometer (IntelliCyt Corp), according to the vendor's protocol. Purified mAbs were assessed 332 at a single dilution (1:10 final, using 2 \u03bcL of purified mAb per reaction), and a control human 333IgG solution with known concentration was used to generate a calibration curve. Data were 334 analyzed using ForeCyt software version 6.2 (IntelliCyt Corp). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Human subject selection and target-specific memory B cells isolation. B cell responses to 95"
        }
    ]
}